Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

Scheid C., Reece D., BEKSAÇ M., Spencer A., Callander N., Sonneveld P., ...Daha Fazla

EUROPEAN JOURNAL OF HAEMATOLOGY, cilt.95, sa.4, ss.316-324, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 95 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1111/ejh.12491
  • Dergi Adı: EUROPEAN JOURNAL OF HAEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.316-324
  • Anahtar Kelimeler: phase 2, relapsed or refractory multiple myeloma, FGFR3, dovitinib, t(4, 14) translocation, GROWTH-FACTOR RECEPTOR-3, KINASE INHIBITOR, STAT ACTIVATION, FGFR3, IDENTIFICATION, CHIR-258, EXPRESSION, PROGNOSIS, THERAPY, PATHWAY
  • Ankara Üniversitesi Adresli: Evet

Özet

ObjectivesApproximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). This study evaluated the efficacy and safety of dovitinib, an RTK inhibitor with in vitro inhibitory activity against FGFR, in patients with relapsed or refractory MM with or without t(4;14) translocation.